Alemtuzumab for patients with chronic lymphocytic leukaemia-Reference-Cited by-同舟云学术

Alemtuzumab for patients with chronic lymphocytic leukaemia

Published:2012-02-15 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Skoetz Nicole¹,Bauer Kathrin¹,Elter Thomas²,Monsef Ina¹,Roloff Verena³,Hallek Michael²,Engert Andreas¹

Affiliation:

1. University Hospital of Cologne; Cochrane Haematological Malignancies Group, Department I of Internal Medicine; Kerpener Str. 62 Cologne Germany 50924

2. University Hospital of Cologne; Department I of Internal Medicine, Center of Integrated Oncology Köln Bonn; Kerpener Str. 62 Cologne Germany 50924

3. MRC Biostatistics Unit; Cambridge UK

Publisher

Wiley

Subject

Pharmacology (medical)

Reference88 articles.

1. FDA drug approval summary: alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia;Demko;Oncologist,2008

2. Dmoszynska A Fetni R Wang Y Belkaci M Sirard C Goldberg M Cytogenetic correlation with efficacy on alemtuzumab (CAM) vs chlorambucil (CHLO) as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL) [abstract] Journal of Clinical Oncology 2006 361

3. Genzyme A phase III study to evaluate the efficacy and safety of front-line therapy with alemtuzumab (Campath, MabCampath) vs chlorambucil in patients with progressive B-cell chronic lymphocytic leukemia (ClinicalTrials.gov identifier: NCT00046683) http://www.clinicaltrials.gov 2003

4. Hillmen P Skotnicki A Robak T Jaksic B Dmoszynka A Sirard C Preliminary phase III efficacy and safety of alemtuzumab vs chlorambucil as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL) [abstract] Journal of Clinical Oncology 2006 339

5. Hillmen P Skotnicki A Robak T Jaksic B Sirard C Mayer J Alemtuzumab (Campath, MabCampath) Has superior progression free survival (PFS) vs chlorambucil as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL) [Abstract] Blood 2006 93

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CD52 and OXPHOS—potential targets in ibrutinib-treated mantle cell lymphoma;Cell Death Discovery;2022-12-31

2. Comparative clinical manifestations and immune effects of cytomegalovirus infections following distinct types of immunosuppression;Clinical Microbiology and Infection;2022-10

3. Cytomegalovirus and Other Herpesviruses;Infectious Complications in Biologic and Targeted Therapies;2022

4. Large Granular Lymphocytic Leukemia: From Immunopathogenesis to Treatment of Refractory Disease;Cancers;2021-09-01

5. Cytomegalovirus DNAemia and disease: current‐era epidemiology, clinical characteristics and outcomes in cancer patients other than allogeneic hematopoietic transplantation;Internal Medicine Journal;2021-08-26